Oventus Clearway Device

The Oventus Clearway Device Has Gained FDA Clearance No ratings yet.

Published On May 3, 2016 | By SDA Editorial Staff | About Snoring

The Oventus Clearway Device Has Gained FDA Clearance for the Treatment of Snoring and Obstructive Sleep Apnea

The Oventus Clearway Device, which is a stop-snoring device produced in Australia, has recently received FDA Clearance – which is a huge step for the company and the product. It’s basically a stop-snoring mouthpiece that treats both snoring and mild sleep apnea by slightly advancing the jaw during sleep, though it also helps to aid in this process by providing a stream of air that bypasses the tongue and soft palate (usual problem-areas for snorers).

The device is made by a company named Oventus Medical Ltd. The fact that it is now cleared by the FDA will mean big positive changes for the company. For one, this helps to validate their tried-and-tested technology on a global level. It also opens them up to sell the device overseas – especially in the US.

The US snoring device market is admittedly huge – with somewhere close to 37 million snorers and 12 to 18 million people who suffer from sleep apnea.

In a quote that was released by the Oventus Managing Director Neil Anderson, it was said that this was the first device that the company had ever had receive such recognition and clearance.

“The O2Vent is the Company’s first medical device to receive FDA clearance, and is consequently an important milestone for us as we strive to bring our innovative product portfolio to the global market to benefit those that suffer from OSA or snore excessively.”

One interesting feature of this device is the fact that it’s actually 3d printed. As companies like Oventus gain access to better and better technology, the level of quality that we’re seeing with devices like this nowadays is truly astounding.

What Does This Mean for the Sleep Market in General?

The global sleep disordered breathing market is, admittedly, a giant market to tap into. It’s worth an estimated $50 billion each year, and shows no signs of slowing down.

With that being said, devices like this (devices that have been shown to work in clinical studies and cleared by the FDA) give snorers a distinct advantage over older, less-effective treatment options.

Not only are they less-expensive than older mouthpieces, but they also simply tend to work better.

Today, now more than ever, people rely on getting a good night’s sleep so that they can perform up-to-par at their job and in their daily lives. With the professional world getting more and more competitive and demanding as time goes on, it’s becoming increasingly important for people to get enough sleep to stay healthy.

Sleep deprivation can lead to a number of different issues. It can make you drowsy during the day, give you an overall feeling of sluggishness, and can even increase your risk for a number of different diseases.

If you would like to learn more about the Oventus Clearway Device in-general, you can visit the official company website here.

One of the most amazing things about this device is the fact that it was so successful during clinical trials that it either eliminated or reduced OSA in 100% of patients – which is incredible! A lot of devices are said to do so in ‘the majority of cases’, but for it to score such high marks and to get such amazing results is actually quite commendable.

Once again, these results just go to show that companies like Oventus are really going above and beyond as better and better technology becomes available. Yes, there have been similar products to this in the past, but many people seem to be of the mind that this is one of the most efficient and effective stop snoring mouthpieces ever – and from the looks of it, that might not be far from the truth.

Please rate your personal experience if you have tried this PRODUCT / BRAND yourself

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.